Comments
Strides Pharma Science has received three observations from the USFDA after the inspection of its formulations facility in Bengaluru
“The formulations facility in Bangalore recently underwent pre-approval product inspection by the US Food and Drug Administration (USFDA). The inspection had ended on August 25, 2018 and the company has been issued Form 483 with 3 observations,” Strides Pharma Science said in a regulatory filing today.
The company believes that the observations are not material in nature and it has already responded to the USFDA. It has recently received a product approval for potassium chloride extended release tablets from the facility.
As per the USFDA, Form 483 is issued to a firm management at the conclusion of an inspection when an investigator (s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Strides Pharma Science shares ended 1.89 per cent down at Rs 499.10 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.